(Q38012022)

27 August 2017

title

Recent advances in our understanding of hepatorenal syndrome (English)

1 reference

27 August 2017

Florence Wong

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

382-391

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2012.96

27 August 2017

exact match

0 references

cites work

Acute kidney injury in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Effects of lipopolysaccharide on TNF-α production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Circulatory function and hepatorenal syndrome in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Acute-on-chronic liver failure: concept, natural history, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Severe sepsis in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Pathogenesis and treatment of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Restricted use of albumin for spontaneous bacterial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Role of albumin treatment in patients with spontaneous bacterial peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Drug insight: the role of albumin in the management of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Model for end-stage liver disease (MELD) and allocation of donor livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Impact of hepatorenal syndrome and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

The course of type 1 hepato-renal syndrome post liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Simultaneous liver-kidney transplantation: evaluation to decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Endotoxin levels in cirrhotic rats with sterile and infected ascites.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

31 March 2020

Cirrhotic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Ischemic renal diseases: new insights into old entities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Acute-on-chronic liver failure: from concept to a new syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Time profile of the haemodynamic effects of terlipressin in portal hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Hepatorenal syndrome, pharmacological therapy, and liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Combined liver and kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Pentoxifylline for alcoholic hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.96

Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt

31 March 2020

1 reference

12 December 2020

Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage

1 reference

12 December 2020

Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation

1 reference

12 December 2020

Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites

1 reference

12 December 2020

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

1 reference

12 December 2020

Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers.

1 reference

12 December 2020

Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2012.96

1 reference

27 August 2017

1 reference